Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab Plus Pembrolizumab Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non‑Small Cell Lung Cancer
Ramucirumab together with pembrolizumab improves overall survival compared with standard chemotherapy in patients with stage IV or recurrent non‑small cell lung cancer previously treated with immunotherapy.
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non‑small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non‑small cell lung cancer than standard chemotherapy.
Determining whether adding ramucirumab to pembrolizumab improves survival versus standard chemotherapy may inform treatment decisions for patients with advanced NSCLC after prior immunotherapy.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT